See more : Haima Automobile Co.,Ltd (000572.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of Chinook Therapeutics, Inc. (KDNY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Chinook Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Galaxia SM, Inc. (011420.KS) Income Statement Analysis – Financial Results
- Freeport-McMoRan Inc. (FCX) Income Statement Analysis – Financial Results
- 79 Resources Ltd. (SNR.CN) Income Statement Analysis – Financial Results
- Tulasee Bio-Ethanol Limited (TULASEEBIOE.BO) Income Statement Analysis – Financial Results
- KMC (Kuei Meng) International Inc. (5306.TW) Income Statement Analysis – Financial Results
Chinook Therapeutics, Inc. (KDNY)
About Chinook Therapeutics, Inc.
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase I/II trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases. Chinook Therapeutics, Inc. is headquartered in Seattle, Washington.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 6.13M | 51.63M | 827.00K | 17.26M | 15.09M | 17.24M | 50.68M | 72.98M |
| Cost of Revenue | 1.72M | 1.69M | 422.00K | 554.00K | 584.00K | 559.00K | 549.00K | 89.00K |
| Gross Profit | 4.41M | 49.94M | 405.00K | 16.70M | 14.50M | 16.68M | 50.13M | 72.89M |
| Gross Profit Ratio | 71.90% | 96.73% | 48.97% | 96.79% | 96.13% | 96.76% | 98.92% | 99.88% |
| Research & Development | 141.21M | 96.99M | 36.05M | 17.01M | 75.84M | 89.38M | 87.72M | 58.65M |
| General & Administrative | 36.29M | 31.90M | 19.07M | 2.96M | 36.04M | 33.75M | 34.28M | 27.81M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 36.29M | 31.90M | 19.07M | 2.96M | 36.04M | 33.75M | 34.28M | 27.81M |
| Other Expenses | 1.72M | 1.69M | 422.00K | 299.00K | 3.99M | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 179.22M | 130.57M | 55.54M | 19.97M | 115.86M | 123.13M | 122.00M | 86.45M |
| Cost & Expenses | 179.22M | 130.57M | 55.54M | 19.97M | 116.45M | 123.69M | 122.54M | 86.54M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 7.18M | 0.00 | 15.00K | 33.00K | 0.00 | 0.00 | 2.22M | 494.00K |
| Depreciation & Amortization | 20.89M | 41.87M | 2.25M | 520.00K | 4.95M | 3.99M | 2.55M | 0.00 |
| EBITDA | -164.20M | -57.17M | -53.98M | -19.45M | -101.36M | -106.45M | -71.86M | -13.56M |
| EBITDA Ratio | -2,679.44% | -110.74% | -6,527.45% | -112.68% | -671.84% | -617.51% | -141.79% | -18.59% |
| Operating Income | -185.08M | -99.04M | -56.23M | -19.97M | -101.36M | -106.45M | -71.86M | -13.56M |
| Operating Income Ratio | -3,020.28% | -191.84% | -6,798.91% | -115.69% | -671.84% | -617.51% | -141.79% | -18.59% |
| Total Other Income/Expenses | 4.81M | -170.00K | -27.40M | -64.82M | 5.22M | 3.23M | 2.18M | -25.74M |
| Income Before Tax | -180.27M | -99.21M | -83.63M | -46.52M | -96.14M | -103.23M | -69.68M | -39.31M |
| Income Before Tax Ratio | -2,941.81% | -192.17% | -10,111.85% | -269.55% | -637.24% | -598.80% | -137.50% | -53.86% |
| Income Tax Expense | 4.34M | 2.09M | -2.00M | 332.00K | 783.00K | 11.36M | -21.46M | -99.00K |
| Net Income | -184.62M | -101.30M | -81.62M | -46.85M | -95.36M | -91.86M | -91.15M | -39.21M |
| Net Income Ratio | -3,012.65% | -196.22% | -9,869.65% | -271.47% | -632.05% | -532.88% | -179.85% | -53.73% |
| EPS | -2.87 | -2.22 | -6.20 | -1.11 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | -2.87 | -2.22 | -6.20 | -1.11 | 0.00 | 0.00 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 64.37M | 45.61M | 13.17M | 42.16M | 78.81B | 72.90B | 65.20B | 44.71B |
| Weighted Avg Shares Out (Dil) | 64.37M | 45.61M | 13.17M | 42.16M | 78.81B | 72.90B | 65.20B | 44.71B |
CHINOOK INVESTOR ALERT : Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Chinook To Contact Him Directly To Discuss Their Options
NEW YORK , May 27, 2023 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Chinook Therapeutics, Inc. ("Chinook" or the "Company") (NASDAQ: KDNY). If you suffered losses exceeding $50,000 investing in...
INVESTIGATION ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Chinook Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / May 24, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Chinook Therapeutics, Inc. ("Chinook" or "the Company") (NASDAQ:KDNY) for...
CHINOOK ALERT: Bragar Eagel & Squire, P.C. is Investigating Chinook Therapeutics, Inc. on Behalf of Chinook Stockholders and Encourages Investors to Contact the Firm
NEW YORK--(BUSINESS WIRE)-- #A--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Chinook Therapeutics, Inc. (“Chinook” or the “Company”) (NASDAQ: KDNY) on behalf of Chinook stockholders. Our investigation concerns whether Chinook has...
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Chinook Therapeutics, Inc. (KDNY) on Behalf of Investors
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Chinook Therapeutics, Inc. (“Chinook” or the “Company”) (NASDAQ: KDNY) investors concerning the Company's possible...
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Chinook Therapeutics, Inc. (KDNY) on Behalf of Investors
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Chinook Therapeutics, Inc. (“Chinook” or the “Company”) (NASDAQ: KDNY) investors concerning the Company's possible violations of federal securities laws. On May 16, 2023, Muddy Waters Research...
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Chinook Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES--(BUSINESS WIRE)---- $KDNY #KDNY--The Schall Law Firm Announces it is Investigating Claims Against Chinook Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm.
The Law Offices of Frank R. Cruz Announces Investigation of Chinook Therapeutics, Inc. (KDNY) on Behalf of Investors
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Chinook Therapeutics, Inc. (“Chinook” or the “Company”) (NASDAQ: KDNY) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder...
KDNY INVESTOR NEWS: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Chinook Therapeutics, Inc. Investors with Losses in Excess of $100K to Inquire About Securities Class Action Investigation – KDNY
NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Chinook Therapeutics, Inc. (NASDAQ: KDNY) resulting from allegations that Chinook may have issued materially misleading business...
Chinook Therapeutics Announces Partnership with Ionis to Develop Antisense Therapy for Rare, Severe Chronic Kidney Disease
SEATTLE, May 16, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY) today announced it has entered a collaboration agreement with Ionis Pharmaceuticals, Inc. for the discovery, development and commercialization of an antisense oligonucleotide (ASO) therapy for a rare, severe...
Chinook Therapeutics (KDNY) Reports Q1 Loss, Tops Revenue Estimates
Chinook Therapeutics (KDNY) came out with a quarterly loss of $0.85 per share versus the Zacks Consensus Estimate of a loss of $0.80. This compares to loss of $0.54 per share a year ago.
Source: https://incomestatements.info
Category: Stock Reports